N

Noile-Immune Biotech Inc
TSE:4893

Watchlist Manager
Noile-Immune Biotech Inc
TSE:4893
Watchlist
Price: 143 JPY -1.38% Market Closed
Market Cap: ¥6.2B

Operating Margin

-10 996.8%
Current
Declining
by 4 715.6%
vs 3-y average of -6 281.3%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-10 996.8%
=
Operating Income
¥-785.5m
/
Revenue
¥7.1m

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-10 996.8%
=
Operating Income
¥-785.5m
/
Revenue
¥7.1m

Peer Comparison

Country Company Market Cap Operating
Margin
JP
Noile-Immune Biotech Inc
TSE:4893
6.2B JPY
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
387B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
184.5B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
174.7B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
121.5B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.2B USD
Loading...
AU
CSL Ltd
ASX:CSL
87.1B AUD
Loading...
NL
argenx SE
XBRU:ARGX
44B EUR
Loading...
US
Seagen Inc
F:SGT
39.3B EUR
Loading...

Market Distribution

Lower than 99% of companies in Japan
Percentile
1st
Based on 6 730 companies
1st percentile
-10 996.8%
Low
-125 500% — 4.2%
Typical Range
4.2% — 10.6%
High
10.6% — 9 743.7%
Distribution Statistics
Japan
Min -125 500%
30th Percentile 4.2%
Median 7%
70th Percentile 10.6%
Max 9 743.7%

Noile-Immune Biotech Inc
Glance View

Market Cap
6.2B JPY
Industry
Biotechnology

Noile-Immune Biotech, Inc. engages in the development of CAR-T cell therapy, a cancer immunotherapy for solid tumors using proprietary technology. The company is headquartered in Minato-Ku, Tokyo-To. The company went IPO on 2023-06-28. The Cancer Immunotherapy Drug Discovery Business segment develops various gene-modified immuno-cell therapies for the treatment of solid tumors, mainly by combining PRIME technology, a platform technology, with therapeutic technologies targeting various antigens expressed by solid tumors. The firm establishes a hybrid business model with two business models: in-house drug discovery, in which the company takes the initiative in drug discovery, and joint pipeline, in which PRIME technology is licensed to other companies for drug development.

Intrinsic Value
49.79 JPY
Overvaluation 65%
Intrinsic Value
Price
N
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
-10 996.8%
=
Operating Income
¥-785.5m
/
Revenue
¥7.1m
What is Noile-Immune Biotech Inc's current Operating Margin?

The current Operating Margin for Noile-Immune Biotech Inc is -10 996.8%, which is below its 3-year median of -6 281.3%.

How has Operating Margin changed over time?

Over the last 2 years, Noile-Immune Biotech Inc’s Operating Margin has decreased from -33.1% to -10 996.8%. During this period, it reached a low of -14 436.1% on Sep 30, 2024 and a high of -33.1% on May 30, 2023.

Back to Top